Skip to main content
ASPEN PHARMACARE HOLDINGS LIMITED logo

ASPEN PHARMACARE HOLDINGS LIMITED — Investor Relations & Filings

Ticker · APN ISIN · ZAE000066692 LEI · 635400ZYSN1IRD5QWQ94 JSE Manufacturing
Open in API
Filings indexed 44 across all filing types
Latest filing 2026-05-29 M&A Activity
Country ZA South Africa
Listing JSE APN

About ASPEN PHARMACARE HOLDINGS LIMITED

https://www.aspenpharma.com/

Aspen Pharmacare Holdings Limited is a global specialty and branded multinational pharmaceutical company with a 170-year heritage, operating across both emerging and developed markets. The company's purpose is to deliver a differentiated portfolio of high quality and affordable medicines, improving health in over 115 countries. Aspen focuses on the marketing and manufacturing of a broad range of post-patent, branded medicines and domestic brands, segmented into Commercial Pharmaceuticals (Injectables, Prescription, and OTC medicines). Its extensive manufacturing network comprises 24 facilities across 15 sites, capable of producing steriles, oral solid dose, liquids, semi-solids, biologicals, and Active Pharmaceutical Ingredients (APIs). These facilities maintain international manufacturing approvals from stringent global regulatory agencies, including the US FDA and the European Directorate for the Quality of Medicines.

Recent filings

Filing Released Lang Actions
Completion of the divestment of Aspen APAC
M&A Activity Classification · 85% confidence The document is an SENS announcement confirming the completion of Aspen’s APAC divestment transaction, detailing proceeds, application of funds, and strategic implications. This is a corporate M&A deal announcement rather than a financial report, dividend notice, or regulatory filing. It does not reference a takeover bid form or proxy, but is clearly related to a sale/divestment transaction. Therefore it falls under M&A Activity (TAR).
2026-05-29 English
Dealing in Securities by a Director and Prescribed Officer
Director's Dealing Classification · 95% confidence The document is a formal announcement detailing share transactions (vesting of deferred bonus shares and subsequent sales) by a director and prescribed officer of the company, which aligns precisely with insider share dealing by senior management. This matches the definition for Director’s Dealing (Code: DIRS).
2026-05-21 English
Dealing in Securities by a Director and Prescribed Officer
Director's Dealing Classification · 100% confidence The document is a notification of dealings in securities by a director and a prescribed officer of Aspen Pharmacare Holdings Limited. It details the vesting and sale of shares related to a Long-Term Retention Share Scheme, including transaction dates, prices, and quantities. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives. The document is not an annual report, earnings release, or any other financial report type, nor is it an announcement of a report. Therefore, the correct classification is Director's Dealing (DIRS). The document length and detail support a high confidence level.
2026-05-05 English
Commercial Release of Locally Manufactured Human Insulin
Regulatory Filings Classification · 95% confidence The document is a brief announcement about Aspen Pharmcare Holdings Limited receiving regulatory approval to commence commercial release of a product (human insulin). It does not contain financial data, management discussion, or detailed report content. It is a regulatory announcement about a commercial milestone, not a financial report or detailed filing. The document length is short (843 characters), and it is an announcement of a business event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-05 English
Resignation of Executive Director
Board/Management Information Classification · 100% confidence The document is a notification about the resignation of an executive director, Mr. Reginald Haman, from the Board of Aspen Pharmacare Holdings Limited. It details the resignation date, expresses appreciation, and mentions a consulting arrangement post-resignation. There is no financial data, no report attached or referenced, and no mention of voting results or other regulatory filings. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-04-30 English
Results of the general meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF THE GENERAL MEETING' and provides detailed voting results from a General Meeting held on 21 April 2026. It references a Circular distributed earlier and reports the approval of an ordinary resolution by shareholders. The content focuses on the announcement of voting outcomes rather than the meeting materials themselves or the full report. The document length is short (2386 characters), and it primarily serves to inform shareholders of the voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.